MERKEL CELL CARCINOMA

This study is testing a combination of three immunotherapy drugs for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer, that has spread and stopped responding to a common first-line treatment. The drugs are designed to work together to reactivate the…

This is a first-in-human study to test the safety and find the right dose of a new cell therapy called BOXR1030. It is for adults with advanced solid tumors (like certain liver, lung, skin, and soft tissue cancers) that have a specific protein marker called GPC3. Doctors will col…

This study is testing if giving the immunotherapy drug cemiplimab to patients before their tumor removal surgery is safe and helps control their cancer. It is for adults with early-stage Merkel cell carcinoma or locally advanced squamous cell carcinoma who are scheduled for surge…

This study is testing whether giving two drugs, lenvatinib and pembrolizumab, before surgery can help people with Merkel cell carcinoma, a rare and aggressive skin cancer. The goal is to shrink the tumor as much as possible to make surgery more effective and potentially improve l…

This early-stage trial is testing the safety of a new combination treatment for people with advanced cancers that have spread and cannot be removed by surgery. Doctors inject immune-stimulating drugs directly into a tumor, then give a small dose of radiation to that same spot. Th…

This early-stage study aims to determine the safety and appropriate dosage of a new experimental cancer drug called FF-10850. The trial will enroll approximately 96 adults with advanced solid tumors that have not responded to standard treatments, including ovarian cancer and Merk…

This study is testing a new combination of immune-boosting drugs for people with advanced cancers whose disease has progressed after treatment with standard immunotherapies like pembrolizumab or nivolumab. It aims to see if adding a drug called NAI to other treatments can help sh…

This small, early-stage study is testing if doing 30 minutes of moderate exercise right before standard immunotherapy can help the treatment work better against certain skin cancers. Researchers will enroll 22 adults with melanoma, squamous cell carcinoma, or Merkel cell carcinom…

This study is testing whether a short, one-cycle course of combined chemotherapy and immunotherapy given before surgery can help treat Merkel cell carcinoma, a rare and aggressive skin cancer. It involves 36 adults with operable cancer who have not had prior systemic treatment. T…

This study is testing whether adding a precise, high-dose radiation treatment (SBRT) to a two-drug immunotherapy combination works better for controlling advanced Merkel cell carcinoma. It will compare the standard immunotherapy pair (nivolumab and ipilimumab) against the same dr…

This study is testing a two-part treatment for patients with advanced skin cancers or rare lymphomas that have not responded to other therapies. First, a modified virus is injected directly into tumors to help the immune system recognize cancer. Then, an immunotherapy drug is giv…